Examples of using Lapatinib in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Lapatinib has not been evaluated in patients with symptomatic cardiac failure.
Lapatinib is a substrate for the transport proteins Pgp and BCRP.
Lapatinib did not significantly inhibit the following enzymes in human liver microsomes.
Lapatinib inhibits the transport proteins Pgp,
The growth inhibitory effects of lapatinib were evaluated in trastuzumab-conditioned cell lines.
The safe use of lapatinib during lactation has not been established.
The half-life of lapatinib measured after single doses increases with increasing dose.
Lapatinib inhibits ErbB-driven tumour cell growth in vitro and in various animal models.
A comparative study between lapatinib and trastuzumab in this patient population has not been conducted.
Lapatinib has been associated with reports of decreases in LVEF see section 4.8.
The following adverse reactions have been reported to be associated with lapatinib.
Peak plasma concentrations(Cmax) of lapatinib are achieved approximately 4 hours after administration.
efficacy of trastuzumab emtansine with that of lapatinib plus capecitabine.
interruption of treatment with lapatinib and letrozole.
In rats, growth retardation was observed in pups which were exposed to lapatinib via breast milk.
Symptomatic LVEF decreases were observed in approximately 0.1% of patients who received lapatinib monotherapy.
Inhibition of P-gp and/or BCRP by lapatinib likely contributed to the increased exposure to pazopanib.
did not result in discontinuation of treatment with lapatinib.
No additional adverse reactions were reported to be associated with lapatinib in combination with trastuzumab.
Lapatinib retained significant activity against breast cancer cell lines selected for long-term growth in trastuzumab-containing medium in vitro.